Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Upstream Bio, Inc.NASDAQ: UPB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $40.59M (cash outflow) rose 48.8% year over year, behind the +98.0% change in trailing-twelve-month net income. Sequentially, it fell 4.4% from the prior quarter. Over 3 fiscal years it compounded at +81.8% a year.
Context
- Net income amounted to 5026.0% of revenue in FY2025, up 2376.0 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$167.46M (+16.7%) for the fiscal year ending Dec 2026, a slowdown from the +128.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$40.59M-4.4% QoQ
- Last fiscal yearDec 2025
- -$143.44M+128.4% YoY
- LTMMar 2026
- -$156.76M+98.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +48.8% | +2.0% | -46.8 pp |
| 1 year | +128.4% | +16.7% | -111.6 pp |
| 3-year CAGR | +81.8% | +0.7% | -81.1 pp |
| 5-year CAGR | +0.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (143.44M) USD
- Year-over-year change
- -128.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (143.44M) | -128.4% |
| FY2024 | 2024-12-31 | (62.81M) | -205.8% |
| FY2023 | 2023-12-31 | (20.54M) | +14.0% |
| FY2022 | 2022-12-31 | (23.87M) | — |
Net Income vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +98.0% is the 2nd highest of 10, against a peer median of +9.3%.
- Net income amounts to 4719.0% of revenue for UPB, versus a peer median of 273.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $500.92M USD | -4.8% | +3.1% | 757.9% | |
| LTM Mar 2026 | $425.15M USD | +161.2% | +46.8% | — | |
| LTM Jun 2026 | $286.04M USD | -8.2% | -1.6% | 2763.6% | |
| LTM Sep 2026 | $263.86M USD | +77.1% | +22.8% | 291.6% | |
| LTM Mar 2026 | $243.25M USD | -26.6% | +24.1% | 112.0% | |
| LTM Mar 2026 | $183.59M USD | +63.4% | +8.1% | 255.7% | |
| LTM Sep 2026 | €179.96M EUR | +11.0% | +31.9% | — | |
| LTM Sep 2026 | $163.2M USD | +9.3% | -10.0% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $156.76M USD | +98.0% | +81.8% | 4719.0% |
| LTM Mar 2026 | $87.84M USD | -118.3% | — | 14.7% | |
| Peer median (excluding UPB) | — | +9.3% | +15.4% | 273.6% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Depreciation & Amortization | 7K | 60K | 89K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.28M | 3.43M | 6M | 10.33M |
| Change in Working Capital | 3.41M | (4.31M) | 1.87M | 589K |
| Accounts Receivables | (412K) | 314K | (515K) | (55K) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 462K | 1.28M | 2.02M | (1.28M) |
| Other Working Capital | 3.36M | (5.9M) | 371K | 1.93M |
| Other Non-Cash Items | 149K | (16.57M) | (4.33M) | 561K |
| Operating Cash Flow | (19.02M) | (37.93M) | (59.17M) | (133.28M) |
| Capital Expenditures | (82K) | (144K) | (511K) | (165K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (128.99M) | (290.61M) | (385.88M) |
| Sales of Investments | 0 | 46.29M | 231.64M | 292.56M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (82K) | (82.84M) | (59.49M) | (93.48M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 9.96M | 129.55M | 272.72M | 2.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (37K) | 118K | (3.74M) | 0 |
| Financing Cash Flow | 9.96M | 129.55M | 418.91M | 2.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.14M) | 8.78M | 300.25M | (224.31M) |
| Free Cash Flow | (19.1M) | (38.07M) | (59.68M) | (133.28M) |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.